Thrust performance of isolated, two-dimensional suppressed plug nozzles with and without ejectors at Mach numbers from 0 to 0.45

A series of two-dimensional plug nozzles was tested with and without ejector shrouds at free stream Mach numbers from 0 to 0.45 and over a range of nozzle pressure ratios from 2 to 4. These nozzles were also tested with and without chute noise suppressors. A two-dimensional plug nozzle has an efficiency of 96.1 percent at an assumed takeoff pressure ratio of 3.0 and Mach 0.36. A 12-chute suppressed nozzle with sidewalls has an efficiency of 81.0 percent (15.1 percent below the unsuppressed nozzle)

Thrust performance of isolated 36-chute suppressor plug nozzles with and without ejectors at Mach numbers from 0 to 0.45

Plug nozzles with chute-type noise suppressors were tested with and without ejector shrouds at free-stream Mach numbers from 0 to 0.45 and over a range of nozzle pressure ratios from 2 to 4. A 36-chute suppressor nozzle with an ejector had an efficiency of 94.6 percent at an assumed takeoff pressure ratio of 3.0 and a Mach number of 0.36. This represents only a 3.4 percent performance penalty when compared with the 98 percent efficiency obtained with a previously tested unsuppressed plug nozzle

Consistency Among Visual Memory Measures

Many instruments have been developed to assess human visual memory functioning, though little research has been done to identify interrelationships among current visual memory measures with each other. The present study explores concurrent validity of the following visual memory tasks: Wechsler Memory Scale - IV (WMS-IV) Visual Reproductions I & II and Designs I & II subtests, the Wide Range Assessment of Memory and Learning, Second edition (WRAML2) Picture Memory and Design Memory subtests, the Brief Visuospatial Memory Test, Revised (BVMT-R), and the Rey Complex Figure Test (RCFT). Two age groups (18-25 and 65- 79) of healthy adults were used to approximate the polar ends of adulthood. Findings demonstrated that the WRAML2 Picture Memory subtest stood apart from the others as a distinctive measure, exhibiting weak correlations with visual memory measures as well as with processing speed (WAIS-IV Coding) and verbal memory (WRAML2 Verbal Learning), regardless of age group measured. In addition, the BVMT-R highlighted significant differences between younger adult performance (compared to same-aged peers) and older adult performance (compared to same-aged peers), suggesting it may be a tool that is more sensitive to decline than other visual memory measures. Results suggest these two measures to be a prudent addition to any neuropsychological battery for their unique contribution

Difficulties in recognizing and treating depression in the elderly : implications for counselors

Diagnosing elderly depression is a difficult, overlooked process. Many elderly seek out family physicians, but few visit mental healthcare professionals (Lyness et al., 1997; Sable & Dunn, 2002). When assessing elderly depression, it is important for counselors to be aware of symptoms, ensuring correct treatment. According to Friedrich ( 1999), it is difficult for healthcare professionals, including counselors, to diagnose depression in the elderly. As elderly may not display traditional depressive symptoms, it is necessary to distinguish between depression, bereavement, and illness, all common in late life. Once depression has been diagnosed, treatments including: medication, psychotherapy, or perhaps the most beneficial combination of the two is available (Seligman, 1990). Counselors must be aware of elderly depression and the many treatments available

Doping Strategies for Small Molecule Organic Hole-transport Materials: Impacts on Perovskite Solar Cell Performance and Stability

Hybrid organic/inorganic perovskite solar cells (PSCs) have dramatically changed the landscape of the solar research community over the past decade, but \u3e25 year stability is likely required if they are to make the same impact in commercial photovoltaics and power generation more broadly. While every layer of a PSC has been shown to impact its durability in power output, the hole-transport layer (HTL) is critical for several reasons: (1) it is in direct contact with the perovskite layer, (2) it often contains mobile ions, like Li+ – which in this case are hygroscopic, and (3) it usually has the lowest thermal stability of all layers in the stack. Therefore, HTL engineering is one method with a high return on investment for PSC stability and lifetime. Research has progressed in understanding design rules for small organic molecule hole-transport materials, yet, when implemented into devices, the same dopants, bis(trifluoromethane)sulfonimide lithium salt (LiTFSI) and tris(2-(1H-pyrazol-1-yl)-4-tert-butylpyridine)cobalt(III) tri[bis(trifluoromethane)sulfonimide] (FK209), are nearly always required for improved charge-transport properties (e.g., increased hole mobility and conductivity). The dopants are notable because they too have been shown to negatively impact PSC stability and lifetime. In response, new research has targeted alternative dopants to bypass these negative effects and provide greater functionality. In this review, we focus on dopant fundamentals, alternative doping strategies for organic small molecule HTL in PSC, and imminent research needs with regard to dopant development for the realization of reliable, long-lasting electricity generation via PSCs

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

Doubling of serum creatinine (equivalent to a 57% decline in the estimated glomerular filtration rate (eGFR)) is an accepted component of a composite kidney endpoint in clinical trials. Smaller declines in eGFR (40%, 50%) have been applied in several recently conducted clinical trials. Here, we assessed the effects of newer kidney protective agents on endpoints including smaller proportional declines in eGFR to compare relative event rates and the magnitude of observed treatment effects. We performed a post hoc analysis of 4401 patients in the CREDENCE, 4304 in the DAPA-CKD, 5734 in the FIDELIO-DKD, and 3668 in the SONAR trials, which assessed the effects of canagliflozin, dapagliflozin, finerenone and atrasentan in patients with chronic kidney disease. Effects of active therapies versus placebo on alternative composite kidney endpoints incorporating different eGFR decline thresholds (40%, 50%, or 57% eGFR reductions from baseline) with kidney failure or death due to kidney failure were compared. Cox-proportional hazards regression models were used to assess and compare treatment effects. During follow-up, event rates were higher for endpoints incorporating smaller versus larger eGFR decline thresholds. Compared to the treatment effects on kidney failure or death due to kidney failure, the magnitude of relative treatment effects was generally similar when considering composite endpoints incorporating smaller declines in eGFR. Hazard ratios for the four interventions ranged from 0.63 to 0.82 for the endpoint incorporating 40% eGFR decline and 0.59 to 0.76 for the endpoint incorporating 57% eGFR decline. Clinical trials incorporating a 40% eGFR decline in a composite endpoint would require approximately half the number of participants compared to a 57% eGFR decline with equivalent statistical power. Thus, in populations at high risk of CKD progression, the relative effects of newer kidney protective therapies appear generally similar across endpoints based on varying eGFR decline thresholds.</p

Controls on zooplankton methane production in the central Baltic Sea

Several methanogenic pathways in oxic surface waters were recently discovered, but their relevance in the natural environment is still unknown. Our study examines distinct methane (CH4) enrichments that repeatedly occur below the thermocline during the summer months in the central Baltic Sea. In agreement with previous studies in this region, we discovered differences in the methane distributions between the western and eastern Gotland Basin, pointing to in situ methane production below the thermocline in the latter (concentration of CH4 14.1±6.1&thinsp;nM, δ13C CH4 −62.9&thinsp;‰). Through the use of a high-resolution hydrographic model of the Baltic Sea, we showed that methane below the thermocline can be transported by upwelling events towards the sea surface, thus contributing to the methane flux at the sea–air interface. To quantify zooplankton-associated methane production rates, we developed a sea-going methane stripping-oxidation line to determine methane release rates from copepods grazing on 14C-labelled phytoplankton. We found that (1) methane production increased with the number of copepods, (2) higher methane production rates were measured in incubations with Temora longicornis (125±49&thinsp;fmol&thinsp;methane&thinsp;copepod−1&thinsp;d−1) than in incubations with Acartia spp. (84±19&thinsp;fmol&thinsp;CH4&thinsp;copepod−1&thinsp;d−1) dominated zooplankton communities, and (3) methane was only produced on a Rhodomonas sp. diet, and not on a cyanobacteria diet. Furthermore, copepod-specific methane production rates increased with incubation time. The latter finding suggests that methanogenic substrates for water-dwelling microbes are released by cell disruption during feeding, defecation, or diffusion from fecal pellets. In the field, particularly high methane concentrations coincided with stations showing a high abundance of DMSP/DMSO-rich Dinophyceae. Lipid biomarkers extracted from phytoplankton- and copepod-rich samples revealed that Dinophyceae are a major food source of the T. longicornis dominated zooplankton community, supporting the proposed link between copepod grazing, DMSP/DMSO release, and the build-up of subthermocline methane enrichments in the central Baltic Sea.</p

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity

CD30 is expressed on Hodgkin lymphomas (HL), many non-Hodgkin lymphomas (NHLs), and non-lymphoid malignancies in children and adults. Tumor expression, combined with restricted expression in healthy tissues, identifies CD30 as a promising immunotherapy target. An anti-CD30 antibody-drug conjugate (ADC) has been approved by the FDA for HL. While anti-CD30 ADCs and chimeric antigen receptors (CARs) have shown promise, their shortcomings and toxicities suggest that alternative treatments are needed. We developed novel anti-CD30 x anti-CD3 bispecific antibodies (biAbs) to coat activated patient T cells (ATCs) ex vivo prior to autologous re-infusions. Our goal is to harness the dual specificity of the biAb, the power of cellular therapy, and the safety of non-genetically modified autologous T cell infusions. We present a comprehensive characterization of the CD30 binding and tumor cell killing properties of these biAbs. Five unique murine monoclonal antibodies (mAbs) were generated against the extracellular domain of human CD30. Resultant anti-CD30 mAbs were purified and screened for binding specificity, affinity, and epitope recognition. Two lead mAb candidates with unique sequences and CD30 binding clusters that differ from the ADC in clinical use were identified. These mAbs were chemically conjugated with OKT3 (an anti-CD3 mAb). ATCs were armed and evaluated in vitro for binding, cytokine production, and cytotoxicity against tumor lines and then in vivo for tumor cell killing. Our lead mAb was subcloned to make a Master Cell Bank (MCB) and screened for binding against a library of human cell surface proteins. Only huCD30 was bound. These studies support a clinical trial in development employing ex vivo-loading of autologous T cells with this novel biAb

Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial

Aim Steroidal mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, are strongly recommended in the treatment of patients with chronic heart failure (HF) with reduced left ventricular ejection fraction (LVEF), but the balance of efficacy and safety in those with higher LVEF has not been well established. Broad use of steroidal MRAs has further been limited in part due to safety concerns around risks of hyperkalaemia, gynecomastia, and kidney dysfunction. These risks may be mitigated by the unique pharmacological properties of the non-steroidal MRA finerenone. The FINEARTS-HF trial is designed to evaluate the long-term efficacy and safety of the selective non-steroidal MRA finerenone among patients with HF with mildly reduced or preserved ejection fraction. Methods FINEARTS-HF is a global, multicentre, event-driven randomized trial evaluating oral finerenone versus matching placebo in symptomatic patients with HF with LVEF ≥40%. Adults (≥40 years) with HF with New York Heart Association class II–IV symptoms, LVEF ≥40%, evidence of structural heart disease, and diuretic use for at least the previous 30 days were eligible. All patients required elevated natriuretic peptide levels: for patients in sinus rhythm, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥300 pg/ml (or B-type natriuretic peptide [BNP] ≥100 pg/ml) were required, measured within 30 days (in those without a recent worsening HF event) or within 90 days (in those with a recent worsening HF event). Qualifying levels of NT-proBNP or BNP were tripled if a patient was in atrial fibrillation at screening. Estimated glomerular filtration rate &lt;25 ml/min/1.73 m2 or serum potassium &gt;5.0 mmol/L were key exclusion criteria. Patients were enrolled irrespective of clinical care setting (whether hospitalized, recently hospitalized, or ambulatory). The primary endpoint is the composite of cardiovascular death and total (first and recurrent) HF events. The trial started on 14 September 2020 and has validly randomized 6001 participants across 37 countries. Approximately 2375 total primary composite events are targeted. Conclusions The FINEARTS-HF trial will determine the efficacy and safety of the non-steroidal MRA finerenone in a broad population of hospitalized and ambulatory patients with HF with mildly reduced or preserved ejection fraction